Literature DB >> 10228046

Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo.

S S Saini1, D W MacGlashan, S A Sterbinsky, A Togias, D C Adelman, L M Lichtenstein, B S Bochner.   

Abstract

Previously, infusions of an anti-IgE mAb (rhumAb-E25) in subjects decreased serum IgE levels, basophil IgE and FcepsilonRIalpha surface density, and polyclonal anti-IgE and Ag-induced basophil histamine release responses. We hypothesized that these effects would be reversed in vivo by discontinuation of infusions and in vitro by exposing basophils to IgE. Subjects received rhumAb-E25 biweekly for 46 wk. Blood samples taken 0-52 wk after rhumAb-E25 were analyzed for serum IgE and basophil expression of IgE, FcepsilonRIalpha, and CD32. Basophil numbers were unaffected by infusions. Eight weeks after infusions, free IgE levels rose in vivo but did not reach baseline. Basophil IgE and FcepsilonRIalpha rose in parallel with free IgE while CD32 was stable. FcepsilonRI densities, measured by acid elution, returned to 80% of baseline, whereas histamine release responses returned to baseline. Basophils cultured with or without IgE or IgG were analyzed for expression of IgE, FcepsilonRIalpha, and CD32. By 7 days with IgE, expression of IgE and FcepsilonRIalpha rose significantly, whereas cultures without IgE declined. IgE culture did not effect CD32. IgG culture did not effect expression of any marker. The present results strongly suggest that free IgE levels regulate FcepsilonRIalpha expression on basophils.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10228046

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

Review 1.  Assessing basophil functional measures during monoclonal anti-IgE therapy.

Authors:  Sarbjit S Saini; Donald W MacGlashan
Journal:  J Immunol Methods       Date:  2012-06-01       Impact factor: 2.303

2.  Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice.

Authors:  Hans D Brightbill; Surinder Jeet; Zhonghua Lin; Donghong Yan; Meijuan Zhou; Martha Tan; Allen Nguyen; Sherry Yeh; Donnie Delarosa; Steven R Leong; Terence Wong; Yvonne Chen; Mark Ultsch; Elizabeth Luis; Sree Ranjani Ramani; Janet Jackman; Lino Gonzalez; Mark S Dennis; Anan Chuntharapai; Laura DeForge; Y Gloria Meng; Min Xu; Charles Eigenbrot; Wyne P Lee; Canio J Refino; Mercedesz Balazs; Lawren C Wu
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

3.  Omalizumab.

Authors:  S Easthope; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Omalizumab: a monoclonal anti-IgE antibody.

Authors:  Paul P Belliveau
Journal:  MedGenMed       Date:  2005-01-27

Review 5.  Beyond immediate hypersensitivity: evolving roles for IgE antibodies in immune homeostasis and allergic diseases.

Authors:  Oliver T Burton; Hans C Oettgen
Journal:  Immunol Rev       Date:  2011-07       Impact factor: 12.988

Review 6.  Effects and mechanisms of actions of Chinese herbal medicines for asthma.

Authors:  Min-Li Hong; Ying Song; Xiu-Min Li
Journal:  Chin J Integr Med       Date:  2011-07-03       Impact factor: 1.978

Review 7.  IgE-dependent signaling as a therapeutic target for allergies.

Authors:  Donald W MacGlashan
Journal:  Trends Pharmacol Sci       Date:  2012-06-30       Impact factor: 14.819

8.  Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge.

Authors:  John A Eckman; Patricia M Sterba; Denise Kelly; Val Alexander; Mark C Liu; Bruce S Bochner; Donald W Macglashan; Sarbjit S Saini
Journal:  J Allergy Clin Immunol       Date:  2009-12-04       Impact factor: 10.793

9.  Relationships between levels of serum IgE, cell-bound IgE, and IgE-receptors on peripheral blood cells in a pediatric population.

Authors:  Eleonora Dehlink; Alexandra H Baker; Elizabeth Yen; Samuel Nurko; Edda Fiebiger
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

10.  Histamine-releasing factor/translationally controlled tumor protein (HRF/TCTP)-induced histamine release is enhanced with SHIP-1 knockdown in cultured human mast cell and basophil models.

Authors:  Jacqueline M Langdon; John T Schroeder; Becky M Vonakis; Anja P Bieneman; Kristin Chichester; Susan M Macdonald
Journal:  J Leukoc Biol       Date:  2008-07-14       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.